Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993 Jun;34(6):808–813. doi: 10.1136/gut.34.6.808

Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.

M F Stolk 1, K J van Erpecum 1, H P Koppeschaar 1, W I de Bruin 1, J B Jansen 1, C B Lamers 1, G P van Berge Henegouwen 1
PMCID: PMC1374267  PMID: 8314514

Abstract

Repeated daily injections of the somatostatin analogue, octreotide (SMS201-995, Sandostatin) are an effective treatment for acromegaly, but lead to gall stone formation in about 50% of cases during longterm treatment. This is probably because of impaired gall bladder contraction. This study examined whether the timing of intermittent injections in relation to meals, or alternatively, continuous 24 hour subcutaneous octreotide infusion (CSOI) might avert adverse effects on gall bladder contraction. In six patients with active acromegaly, gall bladder volume, plasma cholecystokinin (CCK), and pancreatic polypeptide (PP) were measured in the fasting state and after consumption of a fatty meal. Measurements were made on five separate days: (a) without treatment, (b) 45 minutes after 100 micrograms octreotide given subcutaneously, (c) four hours after 100 micrograms octreotide given subcutaneously, (d) eight hours after 100 micrograms octreotide given subcutaneously, and (e) during CSOI of 300 micrograms/24 h for two weeks. Without treatment, postprandial gall bladder contraction was 86.2 (2.1%). Fasting gall bladder volume increased after octreotide injection and was almost doubled during CSOI. Octreotide injections impaired postprandial gall bladder contraction as well as CCK and PP release for at least four hours. Eight hours after injection and during CSOI, postprandial gall bladder contraction was partly restored (43.4% and 50.8% respectively). Postprandial CCK release was normal at eight hours after injection but very low during CSOI. PP release was suppressed by each mode of octreotide treatment. This study indicates that octreotide injections impair postprandial gall bladder contraction for at least four hours. Eight hours after injection and during CSOI, gall bladder contraction is partly restored.

Full text

PDF
808

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adrian T. E., Mitchenere P., Sagor G., Bloom S. R. Effect of pancreatic polypeptide on gallbladder pressure and hepatic bile secretion. Am J Physiol. 1982 Sep;243(3):G204–G207. doi: 10.1152/ajpgi.1982.243.3.G204. [DOI] [PubMed] [Google Scholar]
  2. Ahrendt S. A., McGuire G. E., Pitt H. A., Lillemoe K. D. Why does somatostatin cause gallstones? Am J Surg. 1991 Jan;161(1):177–183. doi: 10.1016/0002-9610(91)90381-m. [DOI] [PubMed] [Google Scholar]
  3. Braverman D. Z., Johnson M. L., Kern F., Jr Effects of pregnancy and contraceptive steroids on gallbladder function. N Engl J Med. 1980 Feb 14;302(7):362–364. doi: 10.1056/NEJM198002143020702. [DOI] [PubMed] [Google Scholar]
  4. Brugge W. R., Brand D. L., Atkins H. L., Lane B. P., Abel W. G. Gallbladder dyskinesia in chronic acalculous cholecystitis. Dig Dis Sci. 1986 May;31(5):461–467. doi: 10.1007/BF01320308. [DOI] [PubMed] [Google Scholar]
  5. Christensen S. E., Weeke J., Orskov H., Møller N., Flyvbjerg A., Harris A. G., Lund E., Jørgensen J. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf) 1987 Sep;27(3):297–306. doi: 10.1111/j.1365-2265.1987.tb01156.x. [DOI] [PubMed] [Google Scholar]
  6. Everson G. T., Braverman D. Z., Johnson M. L., Kern F., Jr A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology. 1980 Jul;79(1):40–46. [PubMed] [Google Scholar]
  7. Fridhandler T. M., Davison J. S., Shaffer E. A. Defective gallbladder contractility in the ground squirrel and prairie dog during the early stages of cholesterol gallstone formation. Gastroenterology. 1983 Oct;85(4):830–836. [PubMed] [Google Scholar]
  8. Fuessl H. S., Carolan G., Williams G., Bloom S. R. Effect of a long-acting somatostatin analogue (SMS 201-995) on postprandial gastric emptying of 99mTc-tin colloid and mouth-to-caecum transit time in man. Digestion. 1987;36(2):101–107. doi: 10.1159/000199407. [DOI] [PubMed] [Google Scholar]
  9. Guillemin R. Somatostatin inhibits the release of acetylcholine induced electrically in the myenteric plexus. Endocrinology. 1976 Dec;99(6):1653–1654. doi: 10.1210/endo-99-6-1653. [DOI] [PubMed] [Google Scholar]
  10. Hanks J. B., Kortz W. J., Andersen D. K., Jones R. S. Somatostatin suppression of canine fasting bile secretion. Gastroenterology. 1983 Jan;84(1):130–137. [PubMed] [Google Scholar]
  11. Ho K. Y., Weissberger A. J., Marbach P., Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med. 1990 Feb 1;112(3):173–181. doi: 10.7326/0003-4819-112-3-173. [DOI] [PubMed] [Google Scholar]
  12. Jansen J. B., Lamers C. B. Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta. 1983 Jul 15;131(3):305–316. doi: 10.1016/0009-8981(83)90100-6. [DOI] [PubMed] [Google Scholar]
  13. Krejs G. J., Orci L., Conlon J. M., Ravazzola M., Davis G. R., Raskin P., Collins S. M., McCarthy D. M., Baetens D., Rubenstein A. Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med. 1979 Aug 9;301(6):285–292. doi: 10.1056/NEJM197908093010601. [DOI] [PubMed] [Google Scholar]
  14. Kutz K., Nüesch E., Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol Suppl. 1986;119:65–72. doi: 10.3109/00365528609087433. [DOI] [PubMed] [Google Scholar]
  15. Lamberts S. W., Uitterlinden P., Verschoor L., van Dongen K. J., del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med. 1985 Dec 19;313(25):1576–1580. doi: 10.1056/NEJM198512193132504. [DOI] [PubMed] [Google Scholar]
  16. Lembcke B., Creutzfeldt W., Schleser S., Ebert R., Shaw C., Koop I. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion. 1987;36(2):108–124. doi: 10.1159/000199408. [DOI] [PubMed] [Google Scholar]
  17. Magnusson I., Einarsson K., Angelin B., Nyberg B., Bergström K., Thulin L. Effects of somatostatin on hepatic bile formation. Gastroenterology. 1989 Jan;96(1):206–212. doi: 10.1016/0016-5085(89)90782-8. [DOI] [PubMed] [Google Scholar]
  18. Marzio L., Capone F., Neri M., Mezzetti A., De Angelis C., Cuccurullo F. Gallbladder kinetics in obese patients. Effect of a regular meal and low-calorie meal. Dig Dis Sci. 1988 Jan;33(1):4–9. doi: 10.1007/BF01536623. [DOI] [PubMed] [Google Scholar]
  19. Marzio L., Neri M., Capone F., Di Felice F., De Angelis C., Mezzetti A., Cuccurullo F. Gallbladder contraction and its relationship to interdigestive duodenal motor activity in normal human subjects. Dig Dis Sci. 1988 May;33(5):540–544. doi: 10.1007/BF01798354. [DOI] [PubMed] [Google Scholar]
  20. McKnight J. A., McCance D. R., Crothers J. G., Atkinson A. B. Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly. BMJ. 1989 Sep 2;299(6699):604–605. doi: 10.1136/bmj.299.6699.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Melmed S. Acromegaly. N Engl J Med. 1990 Apr 5;322(14):966–977. doi: 10.1056/NEJM199004053221405. [DOI] [PubMed] [Google Scholar]
  22. Milenov K., Rakovska A., Kalfin R., Mantovani P. Effect of somatostatin on the canine gallbladder motility. Neuropeptides. 1990 Oct;17(2):75–80. doi: 10.1016/0143-4179(90)90052-z. [DOI] [PubMed] [Google Scholar]
  23. Mitsukawa T., Takemura J., Nishizono F., Nakatsuru K., Ohgo S., Matsukura S. Effects of atropine, proglumide, and somatostatin analogue (SMS 201-995) on bombesin-induced gallbladder contraction and CCK secretion in humans. Am J Gastroenterol. 1989 Nov;84(11):1371–1374. [PubMed] [Google Scholar]
  24. Northfield T. C., Hofmann A. F. Biliary lipid output during three meals and an overnight fast. I. Relationship to bile acid pool size and cholesterol saturation of bile in gallstone and control subjects. Gut. 1975 Jan;16(1):1–11. doi: 10.1136/gut.16.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Plewe G., Beyer J., Krause U., Neufeld M., del Pozo E. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet. 1984 Oct 6;2(8406):782–784. doi: 10.1016/s0140-6736(84)90706-2. [DOI] [PubMed] [Google Scholar]
  26. Poitras P., Yamada T., Walsh J. H. Absence of effect of somatostatin on the guinea pig gallbladder. Can J Physiol Pharmacol. 1980 Feb;58(2):179–182. doi: 10.1139/y80-029. [DOI] [PubMed] [Google Scholar]
  27. Pomeranz I. S., Shaffer E. A. Abnormal gallbladder emptying in a subgroup of patients with gallstones. Gastroenterology. 1985 Mar;88(3):787–791. doi: 10.1016/0016-5085(85)90152-0. [DOI] [PubMed] [Google Scholar]
  28. René E., Danzinger R. G., Hofmann A. F., Nakagaki M. Pharmacologic effect of somatostatin on bile formation in the dog. Enhanced ductular reabsorption as the major mechanism of anticholeresis. Gastroenterology. 1983 Jan;84(1):120–129. [PubMed] [Google Scholar]
  29. Stolk M. F., van Erpecum K. J., van Berge Henegouwen G. P., Kesselring O. F., Hopman W. P. Gallbladder volume and contraction measured by sum-of-cylinders method compared with ellipsoid and area-length methods. Acta Radiol. 1990 Nov;31(6):591–596. [PubMed] [Google Scholar]
  30. Takahashi T., May D., Owyang C. Cholinergic dependence of gallbladder response to cholecystokinin in the guinea pig in vivo. Am J Physiol. 1991 Oct;261(4 Pt 1):G565–G569. doi: 10.1152/ajpgi.1991.261.4.G565. [DOI] [PubMed] [Google Scholar]
  31. Tauber J. P., Babin T., Tauber M. T., Vigoni F., Bonafe A., Ducasse M., Harris A. G., Bayard F. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab. 1989 May;68(5):917–924. doi: 10.1210/jcem-68-5-917. [DOI] [PubMed] [Google Scholar]
  32. Vezina W. C., Paradis R. L., Grace D. M., Zimmer R. A., Lamont D. D., Rycroft K. M., King M. E., Hutton L. C., Chey W. Y. Increased volume and decreased emptying of the gallbladder in large (morbidly obese, tall normal, and muscular normal) people. Gastroenterology. 1990 Apr;98(4):1000–1007. doi: 10.1016/0016-5085(90)90025-v. [DOI] [PubMed] [Google Scholar]
  33. de Jong A. J., Singer M. V., Lamers C. B. Effect of rabbit anti-pancreatic polypeptide serum on postprandial pancreatic exocrine secretion in dogs. Gastroenterology. 1986 Jun;90(6):1926–1931. doi: 10.1016/0016-5085(86)90263-5. [DOI] [PubMed] [Google Scholar]
  34. van Erpecum K. J., van Berge Henegouwen G. P., Stolk M. F., Hopman W. P., Jansen J. B., Lamers C. B. Fasting gallbladder volume, postprandial emptying and cholecystokinin release in gallstone patients and normal subjects. J Hepatol. 1992 Mar;14(2-3):194–202. doi: 10.1016/0168-8278(92)90158-l. [DOI] [PubMed] [Google Scholar]
  35. van Liessum P. A., Hopman W. P., Pieters G. F., Jansen J. B., Smals A. G., Rosenbusch G., Kloppenborg P. W., Lamers C. B. Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab. 1989 Sep;69(3):557–562. doi: 10.1210/jcem-69-3-557. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES